Ionis Pharmaceuticals

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages) This article contains content that is written like an advertisement. Please help improve it by removing promotional content and inappropriate external links, and by adding encyclopedic content written from a neutral point of view. (December 2018) (Learn how and when to remove this message) This article needs to be updated. Please help update this article to reflect recent events or newly available information. (December 2018) (Learn how and when to remove this message)

Ionis Pharmaceuticals, Inc.

Formerly	Isis Pharmaceuticals, Inc.
Company type	Public
Traded as	Nasdaq: IONS Russell 1000 component
Industry	Biotechnology
Founded	1989; 35 years ago (1989)
Founder	Stanley T. Crooke
Headquarters	Carlsbad, California, U.S.
Key people	Brett P. Monia (CEO)[1] Elizabeth L. Hougen (CFO)[2] Joseph Loscalzo (chairman of the board)[3]
Products	nusinersen, inotersen, volanesorsen, plazomicin, mipomersen
Revenue	US$587 million (2022)
Net income	US$−270 million (2022)
Total assets	US$2.53 billion (2022)
Total equity	US$573 million (2022)
Number of employees	796 (December 2022)
Website	ionispharma.com
Footnotes / references [4]

Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza (Nusinersen), Tegsedi (Inotersen), and Waylivra (Volanesorsen) and has four drugs in pivotal studies: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO(a)-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.^[4]

The company was named Isis Pharmaceuticals until December 2015.^[5]